Current stock page

Financial Data

MLYS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

MLYSMineralys Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

Very BearishEdge 5/10
$15.33−$0.17 (−1.10%)

Latest quote

  • Momentum
    23
  • Value
    —
  • Quality
    44
  • Risk resilience
    35
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0$0-$15K$0$0$0
Operating Income-$60.09M-$246.04M-$45.34M-$38.28M-$41.13M-$46.75M-$44.45M-$51.77M
Net Income-$57.33M-$241.07M-$39.34M-$32.23M-$36.93M-$43.27M-$42.21M-$48.95M
EPS-$0.64-$2.85-$0.47-$0.4-$0.52-$0.66-$0.79-$0.98
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$43.1M-$32.56M-$39.47M-$37.89M-$28.87M-$30.17M-$45.49M-$66.84M
Capital Expenditure$0$0$0-$15K$0$0$0$0
Free Cash Flow-$43.1M-$32.56M-$39.47M-$37.9M-$28.87M-$30.17M-$45.49M-$66.84M
Net Cash Provided By Operating Activities-$43.1M-$32.56M-$39.47M-$37.89M-$28.87M-$30.17M-$45.49M-$66.84M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$630.12M$667.85M$652.86M$661.81M$599.95M$335.72M$354.94M$205.9M
Total Debt$98.27M$97.62M$0$0$0$0$0$0
Cash And Cash Equivalents$101.27M$138.27M$112.78M$172.92M$217.6M$101.79M$165.01M$114.09M
Total Liabilities$126.35M$116.94M$14.72M$15.11M$23.52M$22.17M$13.39M$14.65M
Total Stockholders Equity$503.78M$550.92M$638.14M$646.69M$576.43M$313.55M$341.56M$191.26M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.694.23.913.365.452.822.342.78
P/S ratio————————
Debt To Equity0.20.18000000
Free Cash Flow Yield-11.28%-5.99%-5.47%-6.55%-5.46%-21.80%-24.15%-31.34%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.694.23.913.365.452.822.342.78
P/S ratio————————
Return On Equity-73.44%-63.45%-23.78%-23.91%-29.73%-60.84%-55.19%-92.97%
Debt To Equity0.20.18000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-3.52x
Pb2.71x
EPS Growth Yoy-23.08%
Gross Margin0.00%
Operating Margin0.00%
ROE-63.26%
ROIC-64.74%
Debt To Equity0.2
FCF Yield-11.27%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$15.33
Volume1.31M
RSI (14)32.05
MACD-2.07
MACD signal-2.01
MACD histogram-0.06
ADX (14)26.34
SMA (50)$22.66
SMA (200)$26.16
ATR (14)$1.40
Historical volatility (annualized)92.54%
Volume (20-day average)2.01M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score35/100
Beta1.54
Annual volatility61.66%
Max Drawdown-65.59%
Sharpe Ratio-1.48
VaR (95%, 1-day)-6.14%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

MLYS Financial Data FAQ

What is Mineralys Therapeutics, Inc.'s revenue?

Mineralys Therapeutics, Inc.'s revenue is one of the core financial data points for MLYS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Mineralys Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Mineralys Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is MLYS's EPS?

MLYS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Mineralys Therapeutics, Inc.'s net income?

Mineralys Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Mineralys Therapeutics, Inc. generate?

Free cash flow shows how much cash Mineralys Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Mineralys Therapeutics, Inc. have?

Cash and debt help frame MLYS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.